ReviewFrontiers in cellular and infection microbiology2018
Cellular and Molecular Immune Response to Chikungunya Virus Infection.
Review in Frontiers in cellular and infection microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Diagnostic accuracy of serological tests for the diagnosis of Chikungunya virus infection: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Biomarkers of severity and chronification in chikungunya fever: a systematic review and meta-analysis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Pooled it
- Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.JCI insight · 2020Trial
- Single-cell transcriptomic profiling of the splenic and peripheral immune landscape in rhesus macaques during CHIKV infection.Journal of virus eradication · 2026Article
- Chikungunya: global epidemiology, clinical spectrum, and vector control-lessons for China from the 2025 Guangdong outbreak.Archives of toxicology · 2026Review
- Resurgence of Chikungunya virus: rising global threat and challenges in its mitigation.Frontiers in pharmacology · 2026Review
- A Review of the Biology of Chikungunya Virus Highlighting the Development of Current Novel Therapeutic and Prevention Approaches.Pathogens (Basel, Switzerland) · 2025Review
- Pro-Inflammatory Cytokines as Early Predictors of Chronic Rheumatologic Disease Following Chikungunya Virus Infection.Journal of clinical medicine · 2025Review
- Development and proof-of-concept evaluation for a low resource compatible Chikungunya virus diagnostic.PLoS neglected tropical diseases · 2025Article
- Chikungunya virus in Thailand (2020-2023): Epidemiology, clinical features, and genomic insights.PLoS neglected tropical diseases · 2025Article
- Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.Virology journal · 2025Article
- Acute Immunological Biomarkers for Predicting Chronic Rheumatologic Disease After Chikungunya Virus Infection.Tropical medicine and infectious disease · 2025Article
- Long-term persistence of serum IgM antibodies against chikungunya virus in patients with chronic arthralgia.Virology journal · 2025Article
- Comparing human pediatric immune responses to primary infection with dengue, chikungunya and Zika viruses.Frontiers in immunology · 2025Article
- Cytokine Profile in Women Affected by Chikungunya: Analysis of a Prospective Cohort in Northeastern Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- TRIM32 inhibits Venezuelan equine encephalitis virus infection by targeting a late step in viral entry.PLoS pathogens · 2024Article
- Chronic Rheumatologic Disease in Chikungunya Virus Fever: Results from a Cohort Study Conducted in Piedecuesta, Colombia.Tropical medicine and infectious disease · 2024Article
- Acute Chikungunya Virus Infection Triggers a Diverse Range of T Helper Lymphocyte Profiles.Viruses · 2024Article
- Vaccine value profile for Chikungunya.Vaccine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) is a re-emergent arthropod-borne virus (arbovirus) that causes a disease characterized primarily by fever, rash and severe persistent polyarthralgia. In the last decade, CHIKV has become a serious public health problem causing several outbreaks around the world. Despite the fact that CHIKV has been around since 1952, our knowledge about immunopathology, innate and adaptive immune response involved in this infectious disease is incomplete. In this review, we provide an updated summary of the current knowledge about immune response to CHIKV and about soluble immunological markers associated with the morbidity, prognosis and chronicity of this arbovirus disease. In addition, we discuss the progress in the research of new vaccines for preventing CHIKV infection and the use of monoclonal antibodies as a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.